The higher percentage of tumor samples showing a negative staining for TRAIL-R1 and the overall higher intensity staining score for TRAIL-R2 in non-tumor samples indicates a loss of TRAIL-receptors expression in tumor samples vs. matched non tumor tissue samples. This evidence concerns the gene TNFRSF10A and neoplasm.